TrialBlood2022

Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy.

Evangelos Terpos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.